Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Notebook: Price Cuts Planned In France; IPO Window Thrown Open; European Big Pharmas Pursue Major Deals

Executive Summary

Increased optimism about economic growth in Europe has been followed by IPOs becoming more common among the region’s biotech companies; there’s a speculation frenzy about M&A; and with European parliamentary elections in May, further regulatory and legislative changes are likely later in the year.

You may also be interested in...

New Drugs From Biogen, Octapharma, Alcon Passed By Europe’s CHMP

Europe’s top scientific advisory panel, the Committee for Medicinal Products for Human Use, recommended a new long-acting beta-interferon in MS, a highly pure recombinant Factor VIII, and a new combination eye-drop for glaucoma, but confirmed its previous rejections of Novartis’s heart failure therapy, Teva’s oral MS medicine and AB Science’s pancreatic cancer product.

People In The News: Changes At Impax, Isarna, Sorrento, Macrogenics

Actavis global R&D exec G. Frederick Wilkinson joins Impax as president and CEO; FDA veteran Shaw Chen moves to Polaris. On the government side, Senate HELP Cmte. Is slated to review Sylvia Burwell’s nomination for HHS secretary and Michael Hash is retiring from the department. More personnel announcements in this month’s column.

NICE Sends Out Cost Warning By Flatly Rejecting Kadcyla On Price

Not inspired by its clinical effectiveness, NICE has said it will not recommend Roche's “over-priced” Kadcyla for breast cancer.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts